Orlistat: a review of its use in the management of obesity (Q28375925)

https://scigraph.springernature.com/pub.10.2165/00003495-199958040-00015

Europe PubMed Central

title

Orlistat: a review of its use in the management of obesity (English)

0 references

0 references

2

A Markham

0 references

author name string

K M Hvizdos

series ordinal

1

0 references

A Markham

series ordinal

2

0 references

language of work or name

English

0 references

publication date

October 1999

0 references

published in

Drugs

0 references

volume

58

0 references

page(s)

743-60

0 references

issue

4

0 references

exact match

0 references

cites work

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

1 reference

12 December 2020

Influence of dietary composition on the inhibition of fat absorption by orlistat.

1 reference

12 December 2020

The influence of orlistat on the pharmacokinetics and pharmacodynamics of glyburide in healthy volunteers.

1 reference

12 December 2020

The effect of orlistat on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers

1 reference

12 December 2020

The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers

1 reference

12 December 2020

Sibutramine. A review of its contribution to the management of obesity.

1 reference

12 December 2020

Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study.

1 reference

12 December 2020

Guidelines for healthy weight

1 reference

12 December 2020

First clinical studies with orlistat: a short review

1 reference

12 December 2020

The effect of orlistat on the pharmacokinetics of phenytoin in healthy volunteers

1 reference

12 December 2020

Lipase inhibition and hormonal status, body composition and gastrointestinal processing of a liquid high-fat mixed meal in moderately obese subjects

1 reference

12 December 2020

Waist circumference reduction and cardiovascular benefits during weight loss in women

1 reference

12 December 2020

Orlistat in the long-term treatment of obesity in primary care settings

1 reference

12 December 2020

One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor

1 reference

12 December 2020

Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients

1 reference

12 December 2020

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study.

1 reference

12 December 2020

Lipase inhibition: a novel concept in the treatment of obesity

1 reference

12 December 2020

Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults

1 reference

12 December 2020

Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers

1 reference

12 December 2020

Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. I. Producing organism, fermentation, isolation and biological activity

1 reference

12 December 2020

Guidelines for good practice in the diagnosis and treatment of non-insulin-dependent diabetes mellitus. Report of a joint working party of the British Diabetic Association, the Research Unit of the Royal College of Physicians, and the Royal college

1 reference

12 December 2020

Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. The Trials of Hypertension Prevention Collab

1 reference

12 December 2020

Mode of action of orlistat

1 reference

12 December 2020

Flushing away the fat. Weight loss during trials of orlistat was significant, but over half was due to diet

1 reference

12 December 2020

Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin

1 reference

12 December 2020

Influence of orlistat on the regulation of gallbladder contraction in man: a randomized double-blind placebo-controlled crossover study.

1 reference

12 December 2020

Overweight and obesity in the United States: prevalence and trends, 1960-1994

1 reference

12 December 2020

Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18–0647 (tetrahydrolipstatin)

1 reference

12 December 2020

Impairment of health and quality of life in people with large waist circumference.

1 reference

12 December 2020

The interaction of the lipase inhibitor orlistat with ethanol in healthy volunteers

1 reference

12 December 2020

Mode of action of tetrahydrolipstatin: a derivative of the naturally occurring lipase inhibitor lipstatin

1 reference

12 December 2020

Pharmacological treatment of obesity: present status

1 reference

12 December 2020

Effect of the lipase inhibitor orlistat on the pharmacokinetics of four different antihypertensive drugs in healthy volunteers

1 reference

12 December 2020

The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of beta-carotene in healthy volunteers

1 reference

12 December 2020

Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group.

1 reference

12 December 2020

Lack of effect of orlistat on the bioavailability of a single dose of nifedipine extended-release tablets (Procardia XL) in healthy volunteers

1 reference

12 December 2020

The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia

1 reference

12 December 2020

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.

1 reference

12 December 2020

Body Weight and Mortality among Women

1 reference

12 December 2020

Lack of interaction between orlistat and oral contraceptives

1 reference

12 December 2020

Guidelines for the approval and use of drugs to treat obesity. A position paper of The North American Association for the Study of Obesity

1 reference

12 December 2020

Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group

1 reference

12 December 2020

Effect on dietary fat absorption of orlistat, administered at different times relative to meal intake

1 reference

12 December 2020

Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study

1 reference

12 December 2020

Orlistat and weight loss

1 reference

12 December 2020

Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteers

1 reference

12 December 2020

The safety of newly approved medicines: do recent market removals mean there is a problem?

1 reference

12 December 2020

The influence of reduced dietary fat absorption induced by orlistat on the pharmacokinetics of digoxin in healthy volunteers

1 reference

12 December 2020

10.2165/00003495-199958040-00015

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

Dimensions Publication ID

4623119

1026190526

0 references

Fatcat ID

release_v4yjmfgqrrfdvkm3vvb3sop7oi

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/v4yjmfgqrrfdvkm3vvb3sop7oi

24 November 2022

mapped directly with Wikidata item

4623119

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference